Heparin

New Tool Impacts Multi-Billion Dollar Drug

Published in Medical Letter on the CDC and FDA, October 1st, 2000

Scientists at the Massachusetts Institute of Technology (MIT) and their colleagues have announced work they say could impact the multi-billion dollar heparin industry and change how the U.S. Food and Drug Administration (FDA) regulates that common anti-clotting drug.

The work is the first application of a novel analytical tool announced by the same core group of researchers last fall. Other important applications promise to follow, they indicate.

"Periods of great discovery in science are almost always preceded by the development of new tools," writes Prof. Matthew A. Nugent of Boston University in the September 12, 2000, issue of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2000-10-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry